MedTrace Logo

Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting

NCT06786767 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 281

Last updated 2026-03-19

No results posted yet for this study

Summary

The mainstay of asthma treatment are ICSs, mostly and usually combined with LABA. In the past decade LAMA had been accepted as an add-on treatment for patients on GINA treatment Steps 4 and 5. Recently, RCTs proved the efficacy and safety of fixed triple combinations of moderate and high dose of ICS and LABA, LAMA in a very selected asthmatic population, resulting in the market authorization of these products. However, there is a lack of evidence on the real-world effectiveness of these therapies, especially with regards to improvement in symptom scores and quality of life.

Conditions

  • Asthma
  • Asthma Patients
  • Asthma Bronchiale

Interventions

DRUG

BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg

As this is a non-interventional study, it is accordance with routing clinical practice. The assignment of patients to Trimbow 172/5/9 mcg should be made independently from the study.

Sponsors & Collaborators

  • Chiesi Bulgaria

    lead INDUSTRY

Principal Investigators

  • Yavor Y. Ivanov, Asso.Prof. · Group practice for specialized medical care - Asthma Center Pleven

  • Neli L. Rodopska, Pharm.M.Sc · Chiesi Bulgaria

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2026-01-05
Completion
2026-01-05

Countries

  • Bulgaria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06786767 on ClinicalTrials.gov